Ítem
Acceso Abierto

Marcadores de resonancia cardíaca y eventos clínicos en pacientes con cardiopatía chagásica crónica en un centro de latinoamérica

Mostrar el registro sencillo de la publicación
dc.contributor.advisorMedina Zuluaga, Héctor Manuel
dc.contributor.advisorVaquiro Hererra, Eliana
dc.contributor.gruplacGrupo de Investigacion en Cardiologia
dc.creatorRangel Rivera, Diego Alejandro
dc.creator.degreeEspecialista en Cardiología
dc.creator.degreeLevelMaestría
dc.creator.degreetypeFull time
dc.date.accessioned2024-01-11T19:02:21Z
dc.date.available2024-01-11T19:02:21Z
dc.date.created2023
dc.descriptionLa cardiopatía Chagásica crónica (CCC) es una antropozoonosis causada por el Trypanosoma cruzi (T. cruzi) y en Colombia se estima una prevalencia entre el 1-2%. La resonancia magnética cardíaca (RMNC) es el estándar de oro para la evaluación de la función y tamaño cardíaco. Métodos: Este es un estudio observacional, analítico de casos y controles anidado en una cohorte retrospectiva. Se incluyeron todos los pacientes con diagnóstico de CCC que se sometieron a RMNC en la Fundación Cardioinfantil-laCardio entre el 2016 hasta el 2022. Se evaluó un desenlace compuesto (mortalidad por todas las causas, hospitalización por causa cardiovascular, trasplante cardíaco y evento cerebrovascular). Resultados: Se incluyeron un total de 133 pacientes. La mediana de edad de los pacientes fue de 64 años (IQR: 12) con un predominio de mujeres (53,4%). El 97,0% de los pacientes tenían RTG en al menos un segmento miocárdico, siendo de predominio transmural e inferolateral. Durante una mediana de seguimiento de 554 días (IQR: 960) se documentó el evento compuesto en 63 sujetos (47,4%). Se encontró que la FEVI ≤ a 40% tuvo asociación significativa en el análisis multivariado con el primario compuesto (OR: 2,81; p=0,028). Conclusión: Los pacientes de nuestro estudio presentaron una alta incidencia de eventos cardiovasculares y la reducción de la FEVI fue un predictor independiente para su desarrollo.
dc.description.abstractChronic Chagasic heart disease (CCC) is an anthropozoonosis caused by Trypanosoma cruzi (T. cruzi) and in Colombia a prevalence between 1-2% is estimated. Cardiac magnetic resonance imaging (CMR) is the gold standard for cardiac evaluation. Methods: This is an analytical, cohort-type, retrospective study. All patients diagnosed with CHD who underwent CMR at Fundación Cardioinfantil-laCardio from January 2016 to April 2022 were included. A composite outcome (all-cause mortality, hospitalization for cardiovascular causes, heart transplantation, and cerebrovascular event) was evaluated. Results: A total of 133 patients were included. The median age of the patients was 64 years (IQR: 12) with a predominance of women (53.4%). 97.0% of patients had LGE in at least one myocardial segment, predominantly transmural and inferolateral. During a median follow-up of 554 days (IQR: 960), the composite event was documented in 63 subjects (47.4%). LVEF ≤ 40% had a significant association in the multivariate analysis with the primary composite (OR: 2.81; p=0.028). Conclusion: The patients in our study had a high incidence of cardiovascular events and the reduction in LVEF was an independent predictor for their development.
dc.format.extent62 pp
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_41965
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/41965
dc.language.isospa
dc.publisherUniversidad del Rosario
dc.publisher.departmentEscuela de Medicina y Ciencias de la Salud
dc.publisher.programEspecialización en Cardiología
dc.rightsAttribution-NoDerivatives 4.0 International*
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/*
dc.source.bibliographicCitationBonney KM, Luthringer DJ, Kim SA, Garg NJ, Engman DM. Pathology and Pathogenesis of Chagas Heart Disease. Annu Rev Pathol Mech Dis. 2019;14(1):421–47.
dc.source.bibliographicCitationNunes MCP, Dones W, Morillo CA, Encina JJ, Ribeiro AL. Chagas Disease: an Overview of Clinical and Epidemiological Aspects. J Am Coll Cardiol. 2013;62(9):767–76.
dc.source.bibliographicCitationOlivera MJ, Buitrago G. Economic costs of Chagas disease in Colombia in 2017: A social perspective. Int J Infect Dis. 2020;91:196–201.
dc.source.bibliographicCitationSabino EC, Ribeiro AL, Salemi VMC, Di Lorenzo Oliveira C, Antunes AP, Menezes MM, et al. Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic Trypanosoma cruzi –Seropositive Former Blood Donors. Circulation. 2013;127(10):1105–15.
dc.source.bibliographicCitationManne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ. Estimating the burden of Chagas disease in the United States. Dumonteil E, editor. PLoS Negl Trop Dis. 2016;10(11):e0005033
dc.source.bibliographicCitationEchavarría NG, Echeverría LE, Stewart M, Gallego C, Saldarriaga C. Chagas Disease: Chronic Chagas Cardiomyopathy. Curr Probl Cardiol. 2021;46(3):100507.
dc.source.bibliographicCitationArnold JR, McCann GP. Cardiovascular magnetic resonance: applications and practical considerations for the general cardiologist. Heart. 2020;106(3):174–81.
dc.source.bibliographicCitationDuran-Crane A, Rojas CA, Cooper LT, Medina HM. Cardiac magnetic resonance imaging in Chagas’ disease: a parallel with electrophysiologic studies. Int J Cardiovasc Imaging. 2020;36(11):2209–19.
dc.source.bibliographicCitationShen L, Ramires F, Martinez F, Bodanese LC, Echeverría LE, Gómez EA, et al. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Hear Fail. 2017;10(11).
dc.source.bibliographicCitationSilvestre De Sousa A, Salles Xavier S, Rodriguez De Freitas G, Hasslocher-Moreno A. Prevention strategies of cardioembolic ischemic stroke in Chagas’ disease. Arq Bras Cardiol. 2008;91(5):306–11
dc.source.bibliographicCitationRibeiro ALP, Cavalvanti PS, Lombardi F, Nunes MDCP, Barros MVL, Rocha MODC. Prognostic value of signal-averaged electrocardiogram in Chagas disease. J Cardiovasc Electrophysiol. 2008;19(5):502–9.
dc.source.bibliographicCitationRassi A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and Validation of a Risk Score for Predicting Death in Chagas’ Heart Disease. N Engl J Med. 2006;355(8):799–808.
dc.source.bibliographicCitationBern C. Chagas’ Disease. Longo DL, editor. N Engl J Med. 2015;373(5):456–66.
dc.source.bibliographicCitationLewinsohn R. Carlos Chagas and the Discovery of Chagas’s Disease (American Trypanosomiasis). J R Soc Med. 1981;74(6):451–5.
dc.source.bibliographicCitationAraujo-Jorge T, Telleria J, Dalenz JR. History of the discovery of the American Trypanosomiasis (Chagas disease). In: American Trypanosomiasis Chagas Disease. Elsevier; 2017. p. 1–22.
dc.source.bibliographicCitationPino-Marín A, Medina-Rincón GJ, Gallo-Bernal S, Duran-Crane A, Arango Duque ÁI, Rodríguez MJ, et al. Chagas Cardiomyopathy: From Romaña Sign to Heart Failure and Sudden Cardiac Death. Pathogens. 2021;10(5):505.
dc.source.bibliographicCitationMatsuda NM, Miller SM, Evora PRB. The Chronic Gastrointestinal Manifestations of Chagas Disease. Clinics. 2009;64(12):1219–24.
dc.source.bibliographicCitationPérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94.
dc.source.bibliographicCitationde Fuentes-Vicente JA, Gutiérrez-Cabrera AE, Flores-Villegas AL, Lowenberger C, Benelli G, Salazar-Schettino PM, et al. What makes an effective Chagas disease vector? Factors underlying Trypanosoma cruzi-triatomine interactions. Acta Trop. 2018;183:23–31.
dc.source.bibliographicCitationSamuels AM, Clark EH, Galdos-Cardenas G, Wiegand RE, Ferrufino L, Menacho S, et al. Epidemiology of and impact of insecticide spraying on Chagas disease in communities in the Bolivian Chaco. McCall PJ, editor. PLoS Negl Trop Dis. 2013;7(8):e2358.
dc.source.bibliographicCitationRequena-Méndez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DAJ, et al. Prevalence of Chagas Disease in Latin-American Migrants Living in Europe: A Systematic Review and Meta-analysis. Rodrigues MM, editor. PLoS Negl Trop Dis. 2015;9(2):e0003540.
dc.source.bibliographicCitationChao C, Leone JL, Vigliano CA. Chagas disease: Historic perspective. Biochim Biophys Acta - Mol Basis Dis. 2020;1866(5):165689
dc.source.bibliographicCitationLiu Q, Zhou XN. Preventing the transmission of American trypanosomiasis and its spread into non-endemic countries. Infect Dis Poverty. 2015;4(1):60.
dc.source.bibliographicCitationCoura JR, Borges-Pereira J. Chagas disease: What is known and what should be improved: a systemic review. Rev Soc Bras Med Trop. 2012;45(3):286–96.
dc.source.bibliographicCitationBocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Chronic Chagas Heart Disease Management. J Am Coll Cardiol. 2017;70(12):1510–24.
dc.source.bibliographicCitationNunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverría LE, et al. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circulation. 2018;138(12).
dc.source.bibliographicCitationStanaway JD, Roth G. The Burden of Chagas Disease Estimates and Challenges. Glob Heart. 2015;10(3):139–44.
dc.source.bibliographicCitationBestetti RB, Restini CBA. Precordial chest pain in patients with chronic Chagas disease. Vol. 176, International Journal of Cardiology. 2014.
dc.source.bibliographicCitationde Andrade JP, Neto JAM, de Paola AA V, Vilas-Boas F, Oliveira GMM, Bacal F, et al. I Latin American guidelines for the diagnosis and treatment of chagas’ heart disease. Executive summary. Arq Bras Cardiol. 2011;96(6):434–42
dc.source.bibliographicCitationRojas LZ, Glisic M, Pletsch-Borba L, Echeverría LE, Bramer WM, Bano A, et al. Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2018;12(6).
dc.source.bibliographicCitationNunes MCP, Badano LP, Marin-Neto JA, Edvardsen T, Fernández-Golfín C, Bucciarelli-Ducci C, et al. Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging. 2018;19(4).
dc.source.bibliographicCitationAcquatella H. Echocardiography in Chagas Heart Disease. Circulation. 2007;115(9):1124–31.
dc.source.bibliographicCitationViotti RJ, Vigliano C, Laucella S, Lococo B, Petti M, Bertocchi G, et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart. 2004;90(6)
dc.source.bibliographicCitationNunes MCP, Barbosa MM, Ribeiro ALP, Barbosa FBL, Rocha MOC. Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: A prospective follow-up study. J Neurol Sci. 2009;278(1–2):96–101.
dc.source.bibliographicCitationNunes MCP, Kreuser LJ, Ribeiro AL, Sousa GR, Costa HS, Botoni FA, et al. Prevalence and Risk Factors of Embolic Cerebrovascular Events Associated with Chagas Heart Disease. Glob Heart. 2015;10(3):151–7
dc.source.bibliographicCitationChadalawada S, Rassi A, Samara O, Monzon A, Gudapati D, Vargas Barahona L, et al. Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta-analysis. ESC Hear Fail. 2021;8(6).
dc.source.bibliographicCitationRassi A, Rassi SG, Rassi A. Sudden death in chagas’ disease. Arq Bras Cardiol. 2001;76(1):86–96.
dc.source.bibliographicCitationMartins-Melo FR, Alencar CH, Ramos AN, Heukelbach J. Epidemiology of mortality related to Chagas’ disease in Brazil, 1999-2007. PLoS Negl Trop Dis. 2012;6(2).
dc.source.bibliographicCitationRassi A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and Validation of a Risk Score for Predicting Death in Chagas’ Heart Disease. N Engl J Med. 2006;355(8):799–808.
dc.source.bibliographicCitationUmezawa ES, Bastos SF, Camargo ME, Yamauchi LM, Santos MR, Gonzalez A, et al. Evaluation of recombinant antigens for serodiagnosis of Chagas’ disease in South and Central America. J Clin Microbiol. 1999;37(5):1554–60.
dc.source.bibliographicCitationCançado JR. Criteria of Chagas Disease Cure. Mem Inst Oswaldo Cruz. 1999;94(SUPPL. 1).
dc.source.bibliographicCitationSchijman AG, Altcheh J, Burgos JM, Biancardi M, Bisio M, Levin MJ, et al. Aetiological treatment of congenital Chagas’ disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother. 2003;52(3).
dc.source.bibliographicCitationRussomando G, De Tomassone MMC, De Guillen I, Acosta N, Vera N, Almiron M, et al. Treatment of congenital chagas’ disease diagnosed and followed up by the polymerase chain reaction. Am J Trop Med Hyg. 1998;59(3).
dc.source.bibliographicCitationWegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas’ infection. Arzneimittelforschung. 1972;22(9):1624–35.
dc.source.bibliographicCitationMorillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al. Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy. N Engl J Med. 2015;373(14):1295–306.
dc.source.bibliographicCitationDi Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy. JACC Hear Fail. 2017;5(1):28–38.
dc.source.bibliographicCitationLi S, Duan X, Feng G, Sirajuddin A, Yin G, Zhuang B, et al. Multiparametric Cardiovascular Magnetic Resonance in Acute Myocarditis: Comparison of 2009 and 2018 Lake Louise Criteria With Endomyocardial Biopsy Confirmation. Front Cardiovasc Med. 2021;8.
dc.source.bibliographicCitationSenra T, Ianni BM, Costa ACP, Mady C, Martinelli-Filho M, Kalil-Filho R, et al. Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy. J Am Coll Cardiol. 2018;72(21):2577–87.
dc.source.bibliographicCitationVolpe GJ, Moreira HT, Trad HS, Wu KC, Braggion-Santos MF, Santos MK, et al. Left Ventricular Scar and Prognosis in Chronic Chagas Cardiomyopathy. J Am Coll Cardiol. 2018;72(21):2567–76.
dc.source.bibliographicCitationBelloti G, Bocchi EA, Moraes AV de, Higuchi M de L, Barbero-Marcial M, Sosa E, et al. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas’ heart disease. Am Heart J. 1996;131(2):301–7
dc.source.bibliographicCitationMoll-Bernardes RJ, Rosado-de-Castro PH, Camargo GC, Mendes FSNS, Brito ASX, Sousa AS. New Imaging Parameters to Predict Sudden Cardiac Death in Chagas Disease. Trop Med Infect Dis. 2020;5(2):74
dc.source.bibliographicCitationNoya-Rabelo MM, Macedo CT, Larocca T, Machado A, Pacheco T, Torreão J, et al. The presence and extension of myocardial fibrosis in the undetermined form of chagas’ disease: A study using magnetic resonance. Arq Bras Cardiol. 2018;110(2).
dc.source.bibliographicCitationTorreão JA, Ianni BM, Mady C, Naia E, Rassi CH, Nomura C, et al. Myocardial tissue characterization in Chagas’ heart disease by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2015;17(1)
dc.source.bibliographicCitationRegueiro A, García-Álvarez A, Sitges M, Ortiz-Pérez JT, De Caralt MT, Pinazo MJ, et al. Myocardial involvement in Chagas disease: Insights from cardiac magnetic resonance. Int J Cardiol. 2013;165(1).
dc.source.bibliographicCitationVolpe GJ, Moreira HT, Trad HS, Wu K, Braggion-Santos MF, Santos MK, et al. Presence of scar by late gadolinium enhancement is a strong predictor of events in Chagas Heart Disease. J Cardiovasc Magn Reson. 2014;16(S1).
dc.source.bibliographicCitationMoreira HT, Volpe GJ, Marin-Neto JA, Ambale-Venkatesh B, Nwabuo CC, Trad HS, et al. Evaluation of Right Ventricular Systolic Function in Chagas Disease Using Cardiac Magnetic Resonance Imaging. Circ Cardiovasc Imaging. 2017;10(3).
dc.source.bibliographicCitationPinheiro MVT, Moll-Bernardes RJ, Camargo GC, Siqueira FP, de Azevedo CF, de Holanda MT, et al. Associations between cardiac magnetic resonance T1 mapping parameters and ventricular arrhythmia in patients with chagas disease. Am J Trop Med Hyg. 2020;103(2).
dc.source.bibliographicCitationNardi Gemme C, Silva TQAC, Martins LC, da Silva LM, Paim LR, Sposito A, et al. Diffuse Myocardial Fibrosis and Cardiomyocyte Diameter Are Associated With Heart Failure Symptoms in Chagas Cardiomyopathy. Front Cardiovasc Med. 2022;9(June):1–12.
dc.source.bibliographicCitationMello RP de, Szarf G, Schvartzman PR, Nakano EM, Espinosa MM, Szejnfeld D, et al. Delayed enhancement cardiac magnetic resonance imaging can identify the risk for ventricular tachycardia in chronic Chagas’ heart disease. Arq Bras Cardiol. 2012;98(5):421–30
dc.source.bibliographicCitationMansur AP, Pereira-Barretto AC, del Carlo CH, Ianni BM, Avakian SD, Gonçalinho GHF, et al. Sex Differences in Prognosis of Heart Failure Due to Chronic Chagas Cardiomyopathy. JACC Hear Fail. 2023;11(9):1284–6.
dc.source.bibliographicCitationAcosta IC, Pérez-Tanoira R, Prieto-Pérez L, Úbeda AC, Álvarez Álvarez B, Antoranz PA, et al. Chagas’ heart disease: Descriptive analysis of 141 patients in a hospital of Madrid, Spain. Travel Med Infect Dis. 2020;37:101690.
dc.source.bibliographicCitationKammerlander AA, Wiesinger M, Duca F, Aschauer S, Binder C, Zotter Tufaro C, et al. Diagnostic and Prognostic Utility of Cardiac Magnetic Resonance Imaging in Aortic Regurgitation. JACC Cardiovasc Imaging. 2019;12(8):1474–83.
dc.source.bibliographicCitationYokota H, Heidary S, Katikireddy CK, Nguyen P, Pauly JM, McConnell M V., et al. Quantitative characterization of myocardial infarction by cardiovascular magnetic resonance predicts future cardiovascular events in patients with ischemic cardiomyopathy. J Cardiovasc Magn Reson. 2008;10(1):17.
dc.source.bibliographicCitationGulati A, Japp AG, Raza S, Halliday BP, Jones DA, Newsome S, et al. Absence of Myocardial Fibrosis Predicts Favorable Long-Term Survival in New-Onset Heart Failure. Circ Cardiovasc Imaging. 2018;11(9).
dc.source.bibliographicCitationMarin-Neto JA, Simões M V., Ayres-Neto EM, Attab-Santos JL, Gallo Jr. L, Amorim DS, et al. Studies of the coronary circulation in Chagas’ heart disease. Sao Paulo Med J. 1995;113(2):826–34.
dc.source.bibliographicCitationGomes VAM, Alves GF, Hadlich M, Azevedo CF, Pereira IM, Santos CRF, et al. Analysis of Regional Left Ventricular Strain in Patients with Chagas Disease and Normal Left Ventricular Systolic Function. J Am Soc Echocardiogr. 2016;29(7).
dc.source.bibliographicCitationLee-Felker SA, Thomas M, Felker ER, Traina M, Salih M, Hernandez S, et al. Value of cardiac MRI for evaluation of chronic Chagas disease cardiomyopathy. Clin Radiol. 2016;71(6):618.e1-618.e7.
dc.source.bibliographicCitationSantos JB de F, Gottlieb I, Tassi EM, Camargo GC, Atié J, Xavier SS, et al. Fibrose Cardíaca e Mudanças Evolutivas na Função Ventricular Esquerda em Pacientes com Cardiopatia Chagásica Crônica. Arq Bras Cardiol. 2021;117(6).
dc.source.bibliographicCitationMatta JAM da, Aras R, Macedo CRB de, Cruz CG da, Netto EM. Stroke Correlates in Chagasic and Non-Chagasic Cardiomyopathies. Saks V, editor. PLoS One. 2012;7(4):e35116.
dc.source.bibliographicCitationCerqueira-Silva T, Gonçalves BMM, Pereira CB, Porto LM, Marques MEL, Santos LSB, et al. Chagas disease is an independent predictor of stroke and death in a cohort of heart failure patients. Int J Stroke. 2022;17(2):180–8.
dc.source.bibliographicCitationLage TAR, Tupinambás JT, Pádua LB de, Ferreira M de O, Ferreira AC, Teixeira AL, et al. Stroke in Chagas disease: from pathophysiology to clinical practice. Rev Soc Bras Med Trop. 2022;55.
dc.source.bibliographicCitationMoreira HT, Volpe GJ, Mesquita GM, Braggion-Santos MF, Pazin-Filho A, Marin-Neto JA, et al. Association of left ventricular abnormalities with incident cerebrovascular events and sources of thromboembolism in patients with chronic Chagas cardiomyopathy. J Cardiovasc Magn Reson. 2022;24(1)
dc.source.bibliographicCitationde Brito ASX, Moll-Bernardes RJ, Pinheiro MVT, Camargo GC, Siqueira FPR, Oliveira RS, et al. Autonomic denervation, myocardial hypoperfusion and fibrosis may predict ventricular arrhythmia in the early stages of Chagas cardiomyopathy. J Nucl Cardiol. 2023 Dec;30(6):2379-2388.
dc.source.bibliographicCitationTassi EM, Continentino MA, Nascimento EM, Pereira Bde B, Pedrosa RC. Relationship between fibrosis and ventricular arrhythmias in Chagas heart disease without ventricular dysfunction. Arq Bras Cardiol. 2014 May;102(5):456-64.
dc.source.bibliographicCitationMello RP de, Szarf G, Schvartzman PR, Nakano EM, Espinosa MM, Szejnfeld D, et al. Realce Tardio miocárdico por Ressonância Magnética Cardíaca pode identificar risco para Taquicardia Ventricular na Cardiopatia Chagásica Crônica. Arq Bras Cardiol. 2012;98(5):421–30.
dc.source.bibliographicCitationFlynn D, Ford GA, Rodgers H, Price C, Steen N, Thomson RG. A time series evaluation of the FAST national stroke awareness campaign in England. PLoS One. 2014;9(8).
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subjectEnfermedad de chagas
dc.subjectResonancia cardíaca
dc.subjectPronóstico
dc.subjectFalla cardíaca
dc.subject.keywordChagas disease
dc.subject.keywordCardiac resonance
dc.subject.keywordPrognosis
dc.subject.keywordHeart failure
dc.titleMarcadores de resonancia cardíaca y eventos clínicos en pacientes con cardiopatía chagásica crónica en un centro de latinoamérica
dc.title.TranslatedTitleCardiac resonance markers and clinical events in patients with chronic chagasic heart disease in a Latin American center
dc.typebachelorThesis
dc.type.documentTrabajo de grado
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTrabajo de grado
local.department.reportEscuela de Medicina y Ciencias de la Salud
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Marcadores_de_resonancia_cardíaca_Rangel_Rivera_Diego_Alejandro.pdf
Tamaño:
1.02 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Especialización en Cardiología